Home > Field of Cooperation > Health Research > Development of neutralizing agents targeting glycopeptides highly conserved in SARS-CoV-2 mutant strains
Development of neutralizing agents targeting glycopeptides highly conserved in SARS-CoV-2 mutant strains |
| Principal Investigator / Affiliation | Hiroaki Tateno (Group Leader) / National Institute of Advanced Industrial Science and Technology  Japan |
|---|---|
Mohamed Abdel-Mohsen (Associate Professor) / The Wistar Institute  USA |
|
Deanpen Japrung (Research group director) / National Science and Technology Development Agency  Thailand |
|
| Year Adopted | 2022 |
| Research Period | 3 years |
| General Description of the Research Project | This collaborative research aims to develop neutralizing agents such as monoclonal antibodies and aptamers targeting the glycopeptides that are essential for SARS-CoV-2 infection and highly conserved in various mutant strains. The agents specific to the glycopeptides will be produced and analyzed by the integration of glycobiology, chemistry, and virology. The structure of the agents complexed with S protein will also be analyzed. These agents should be able to prevent/treat infections with SARS-CoV-2 variants of concerns or future emerging variants |
| Photo Gallery | |
| Reports | |
| Links |
Researchers
| Principal Investigator / Country of Research Team | 
Hiroaki Tateno Japan
Mohamed Abdel-Mohsen the United States
Deanpen Japrung Thailand |
|---|